These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 31140123)

  • 1. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
    Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
    Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Song J; Ma Q; Gao W; Cong Z; Xie J; Zimmerman Z; Belton L; Franklin J; Palmer S
    Adv Ther; 2019 Apr; 36(4):950-961. PubMed ID: 30758745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
    Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
    Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients.
    Shah B; Chen JMH; Wu JJ; Feng C; Zhou L; Park JE; Hadjiivassileva T; Kerbauy FR; Wade SW; Keeping S
    Adv Ther; 2023 Dec; 40(12):5383-5398. PubMed ID: 37801234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
    Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
    Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M
    Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
    Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
    Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
    Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
    Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment.
    Marks DI; van Oostrum I; Mueller S; Welch V; Vandendries E; Loberiza FR; Böhme S; Su Y; Stelljes M; Kantarjian HM
    Cancer Med; 2019 Oct; 8(13):5959-5968. PubMed ID: 31436395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
    Jabbour EJ; Sasaki K; Ravandi F; Short NJ; Garcia-Manero G; Daver N; Kadia T; Konopleva M; Jain N; Cortes J; Issa GC; Jacob J; Kwari M; Thompson P; Garris R; Pemmaraju N; Yilmaz M; O'Brien SM; Kantarjian HM
    Cancer; 2019 Aug; 125(15):2579-2586. PubMed ID: 30985931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting.
    Russell-Smith A; Murphy L; Nguyen A; Blauer-Peterson C; Terpenning M; Cao F; Li S; Bancroft T; Webb N; Dorman S; Shah R
    J Comp Eff Res; 2024 Feb; 13(2):e230142. PubMed ID: 38099517
    [No Abstract]   [Full Text] [Related]  

  • 14. Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.
    Fracchiolla NS; Sciumè M; Papayannidis C; Vitale A; Chiaretti S; Annunziata M; Giglio F; Salutari P; Forghieri F; Lazzarotto D; Lunghi M; Imovilli A; Scappini B; Bonifacio M; Dargenio M; Gurrieri C; Todisco E; Defina M; Del Principe MI; Zappasodi P; Cerrano M; Santoro L; Tagliaferri E; Barozzi E; De Roberto P; Canzi M; Buzzatti E; Sartor C; Passamonti F; Foà R; Curti A
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.
    Kayser S; Sartor C; Giglio F; Bruno A; Webster J; Chiusolo P; Saraceni F; Guerzoni S; Pochintesta L; Borlenghi E; Marconi G; Zacheo I; Cerrano M; Salutari P; Restuccia F; Abbenante M; Levis MJ; Schlenk RF; Papayannidis C
    Haematologica; 2024 May; 109(5):1385-1392. PubMed ID: 38058184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system.
    Lee TY; Chen HY; Chen TY; Li SS; Fang WT; Wen YC; Lo YW; Ou HT
    Eur J Health Econ; 2020 Sep; 21(7):1105-1116. PubMed ID: 32506280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
    Jabbour EJ; Gökbuget N; Kantarjian HM; Thomas X; Larson RA; Yoon SS; Ghobadi A; Topp MS; Tran Q; Franklin JL; Forman SJ; Stein AS
    Cancer; 2019 Dec; 125(23):4181-4192. PubMed ID: 31433496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Marks DI; Kebriaei P; Stelljes M; Gökbuget N; Kantarjian H; Advani AS; Merchant A; Stock W; Cassaday RD; Wang T; Zhang H; Loberiza F; Vandendries E; DeAngelo DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1720-1729. PubMed ID: 31039409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
    Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
    Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.